This retrospective cohort study assessed adult patients with acute myeloid leukemia (AML) who received FLT3 and/or NPM1 testing treated at any Veterans Health Administration (VHA) facility or at Vanderbilt University Medical Center (VUMC) between January 2006 and December 2016. The gene discussed is NPM1; the disease is acute myeloid leukemia.